Cooper Companies (NASDAQ:COO) price target increased to $115.00

Cooper Companies (NASDAQ:COO – Get Free Report) raised their target price on Wells Fargo & Company from $110.00 to $115.00 in a report on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the medical device company’s stock. Wells Fargo & Company’s price target indicates a potential upside of 21.64% from the stock’s current price.

Several other research firms have also recently commented on COO. Robert W. Baird upped their target price on shares of Cooper Companies from $116.00 to $118.00 and gave the stock an “outperform” rating in a research report on Friday, May 31st. Jefferies Financial Group upgraded Cooper Companies from a “hold” rating to a “buy” rating and upped their target price for the stock from $107.00 to $115.00 in a report on Tuesday, July 16th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a report on Friday, August 23rd. Finally, Piper Sandler upped their target price on shares of Cooper Companies from $115.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Cooper Companies presently has an average rating of “Moderate Buy” and an average target price of $113.16, according to MarketBeat .

Read our latest research report on COO

Cooper Companies Stock Performance

COO stock opened at $94.54 on Thursday. The stock has a 50-day moving average of $90.97 and a 200-day moving average of $94.04. The company has a market cap of $18.82 billion, a PE ratio of 55.61, a P/E/G ratio of 2.34 and a beta of 0.98. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.95, and a quick ratio of 1.14. Cooper Companies has a one year low of $75.93 and a one year high of $104.07.

Cooper Companies (NASDAQ:COO – Get Free Report ) last released its quarterly earnings data on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.91 by $0.05. Cooper Companies had a return on equity of 8.87% and a net margin of 9.11%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $997.30 million. In the same quarter last year, the company posted earnings per share of $0.84. The company’s quarterly revenue was up 7.8% year over year. On average, equities research analysts forecast that Cooper Companies will post 3.57 EPS for the current fiscal year.

Institutional inputs and outputs

A number of hedge funds have recently added to or reduced their stakes in COO. Benjamin F. Edwards & Company Inc. raised its stake in Cooper Companies by 248.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 244 shares of the medical device company’s stock worth $25,000 after purchasing an additional 174 shares in the last quarter. Inçalta Capital LLC bought a new position in Cooper Companies in the second quarter worth about $25,000. Covestor Ltd boosted its holdings in shares of Cooper Companies by 305.9% in the first quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock valued at $28,000 after acquiring an additional 208 shares in the last quarter. Crewe Advisors LLC grew its position in shares of Cooper Companies by 286.4% in the 2nd quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 252 shares in the the last quarter. Finally, Global Retirement Partners LLC grew its position in shares of Cooper Companies by 358.6% in the first quarter. Global Retirement Partners LLC now owns 321 shares of the medical device company’s stock worth $33,000 after purchasing an additional 251 shares during the last quarter. Hedge funds and other institutional investors own 24.39% of the company’s shares.

Cooper Companies Company Profile

(Get a free report)

Cooper Companies, Inc, together with its subsidiaries, develops, manufactures and markets contact lens wearers. The company operates through two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lenses, including lenses that correct myopia and hyperopia; and toric and multifocal lenses comprising lenses that correct vision problems such as astigmatism, presbyopia and myopia in the Americas, Europe, the Middle East, Africa and Asia Pacific.

Recommended articles

Get daily news and ratings for Cooper companies – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cooper Companies and related companies with MarketBeat.com’s FREE daily email newsletter.